Clinical and Economic Outcomes of a Pharmacogenomics-enriched Comprehensive Medication Management Program in a Self-insured Employee Population

Abstract

Abstract Clinical and economic outcomes from a pharmacogenomics-enriched comprehensive medication management program were evaluated over 26-months in a self-insured employee population (n=452 participants; n=1,500 controls) using propensity matched pre-post design with adjusted negative binomial and linear regression models. After adjusting for baseline covariates, program participation was associated with 39% fewer inpatient (p=0.05) and 39% fewer emergency department (p=0.002) visits, and with 21% more outpatient visits (p<0.001) in the follow-up period compared to the control group. Results show pharmacogenomics-enriched comprehensive medication management can favorably impact healthcare utilization in a self-insured employer population by reducing emergency department and inpatient visits and can offer potential for cost savings. Self-insured employers may consider implementing pharmacogenomics-enriched comprehensive medication management to improve the healthcare of their employees.